Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C).
作者信息
Bhat Chandrika S, Shetty Rakshay, Ramesh Deepak, Banu Afreen, Ramanan Athimalaipet V
机构信息
Pediatric Rheumatology Services, Rainbow Children's Hospital, Bangalore, Karnataka, India.
Pediatric Intensive Care Services, Rainbow Children's Hospital, Bangalore, Karnataka, India.
出版信息
Indian Pediatr. 2021 Oct 15;58(10):994-996. doi: 10.1007/s13312-021-2340-1.
Abstract
摘要
相似文献
1
Anakinra in Refractory Multisystem Inflammatory Syndrome in Children (MIS-C).阿那白滞素治疗儿童难治性多系统炎症综合征（MIS-C）
Indian Pediatr. 2021 Oct 15;58(10):994-996. doi: 10.1007/s13312-021-2340-1.
2
Efficacy of anakinra on rebound of multisystem inflammatory syndrome.阿那白滞素对多系统炎症综合征复发的疗效。
Pediatr Int. 2022 Jan;64(1):e15337. doi: 10.1111/ped.15337.
3
Multisystem inflammatory syndrome in adults: A rare sequela of SARS-CoV-2 infection.成人多系统炎症综合征：一种罕见的 SARS-CoV-2 感染后遗症。
Int J Infect Dis. 2021 Jul;108:209-211. doi: 10.1016/j.ijid.2021.05.050. Epub 2021 May 24.
4
Effectiveness of early Anakinra on cardiac function in children with multisystem inflammatory syndrome of COVID-19: a systematic review.COVID-19 相关多系统炎症综合征患儿早期使用阿那白滞素对心功能的疗效：系统评价。
BMC Infect Dis. 2024 Aug 21;24(1):847. doi: 10.1186/s12879-024-09581-w.
5
SARS-CoV-2 multisystem inflammatory syndrome in an adult presenting with polyarthritis treated with anakinra.一名成年患者出现多关节炎，经阿那白滞素治疗的新型冠状病毒2型多系统炎症综合征。
Rheumatology (Oxford). 2022 Feb 2;61(2):e33-e34. doi: 10.1093/rheumatology/keab697.
6
Recent research on the application of biologics in the treatment of multisystem inflammatory syndrome in children after SARS-CoV-2 infection.近期关于生物制剂在治疗 SARS-CoV-2 感染后儿童多系统炎症综合征中的应用的研究。
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Feb 15;24(2):216-222. doi: 10.7499/j.issn.1008-8830.2111005.
7
Is it all MIS-C? Unusual findings in a series of nine German patients with multi-system inflammatory syndrome in children after SARS-CoV-2 infection.都是 MIS-C 吗？在一系列 9 例德国 SARS-CoV-2 感染后儿童多系统炎症综合征患者中发现的不常见表现。
Int J Infect Dis. 2021 May;106:405-408. doi: 10.1016/j.ijid.2021.04.044. Epub 2021 Apr 20.
8
Distinct clinical and immunological features of SARS-CoV-2-induced multisystem inflammatory syndrome in children.儿童严重急性呼吸综合征冠状病毒 2 诱导的多系统炎症综合征的独特临床和免疫学特征。
J Clin Invest. 2020 Nov 2;130(11):5942-5950. doi: 10.1172/JCI141113.
9
Oral manifestations of multisystemic inflammatory syndrome in children (MIS-C) and Kawasaki disease associated to COVID-19: A systematic review.COVID-19 相关儿童多系统炎症综合征（MIS-C）和川崎病的口腔表现：系统评价。
Spec Care Dentist. 2022 May;42(3):266-280. doi: 10.1111/scd.12669. Epub 2021 Nov 18.
10
Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children, regardless of disease severity.早期阿那白滞素治疗可改善儿童多系统炎症综合征的心脏结局，与疾病严重程度无关。
Rheumatology (Oxford). 2024 Feb 1;63(2):366-375. doi: 10.1093/rheumatology/kead381.
引用本文的文献
1
Progress on diagnosis and treatment of multisystem inflammatory syndrome in children.儿童多系统炎症综合征的诊断与治疗进展
Front Immunol. 2025 Feb 19;16:1551122. doi: 10.3389/fimmu.2025.1551122. eCollection 2025.
2
Kawasaki Disease-Associated Cytokine Storm Syndrome.川崎病相关细胞因子风暴综合征。
Adv Exp Med Biol. 2024;1448:365-383. doi: 10.1007/978-3-031-59815-9_25.
3
Impact of anakinra use on clinical outcomes in children with moderate or severe multisystem inflammatory syndrome in children: a propensity score matched retrospective cohort study.阿那白滞素治疗儿童中重度儿童多系统炎症综合征的临床结局影响：一项倾向评分匹配回顾性队列研究。
Pediatr Rheumatol Online J. 2023 Nov 23;21(1):141. doi: 10.1186/s12969-023-00924-6.
4
Kawasaki disease following SARS-CoV-2 infection: Stronger inflammation with no increase in cardiac complications.新型冠状病毒感染后发生的川崎病：炎症反应更强但心脏并发症未增加。
Front Pediatr. 2022 Nov 17;10:1036306. doi: 10.3389/fped.2022.1036306. eCollection 2022.
5
Anakinra treatment in multisystemic inflammatory syndrome in children (MIS-C) associated with COVID-19.阿那白滞素治疗与新型冠状病毒肺炎相关的儿童多系统炎症综合征（MIS-C）。
Front Pediatr. 2022 Aug 18;10:942455. doi: 10.3389/fped.2022.942455. eCollection 2022.
6
State of the Globe: Multisystem Inflammatory Syndrome in Children - Did the COVID-19 Pandemic Actually Handle Kids with Kids-Glove?全球状况：儿童多系统炎症综合征——新冠疫情对儿童真的是呵护备至吗？
J Glob Infect Dis. 2021 Nov 30;13(4):157-158. doi: 10.4103/jgid.jgid_307_21. eCollection 2021 Oct-Dec.
7
Timely Recognition and Early Multi-Step Antinflammatory Therapy May Prevent ICU Admission of Patients With MIS-C: Proposal for a Severity Score.及时识别和早期多步骤抗炎治疗可能预防儿童多系统炎症综合征患者入住重症监护病房：严重程度评分建议
Front Pediatr. 2021 Dec 20;9:783745. doi: 10.3389/fped.2021.783745. eCollection 2021.
本文引用的文献
1
Case Report: Case Series of Children With Multisystem Inflammatory Syndrome Following SARS-CoV-2 Infection in Switzerland.病例报告：瑞士SARS-CoV-2感染后多系统炎症综合征患儿病例系列
Front Pediatr. 2021 Jan 5;8:594127. doi: 10.3389/fped.2020.594127. eCollection 2020.
2
American College of Rheumatology Clinical Guidance for Multisystem Inflammatory Syndrome in Children Associated With SARS-CoV-2 and Hyperinflammation in Pediatric COVID-19: Version 2.美国风湿病学会儿童与 SARS-CoV-2 相关的多系统炎症综合征和儿科 COVID-19 中过度炎症的临床指导：第 2 版。
Arthritis Rheumatol. 2021 Apr;73(4):e13-e29. doi: 10.1002/art.41616. Epub 2021 Feb 15.
3
A national consensus management pathway for paediatric inflammatory multisystem syndrome temporally associated with COVID-19 (PIMS-TS): results of a national Delphi process.与 COVID-19 相关的儿童炎症性多系统综合征的国家共识管理路径（PIMS-TS）：全国德尔菲研究的结果。
Lancet Child Adolesc Health. 2021 Feb;5(2):133-141. doi: 10.1016/S2352-4642(20)30304-7. Epub 2020 Sep 18.
4
Hyperinflammatory Syndrome in Children Associated With COVID-19: Need for Awareness.儿童 COVID-19 相关超高炎症综合征：需要提高认识。
Indian Pediatr. 2020 Oct 15;57(10):929-935. doi: 10.1007/s13312-020-1997-1. Epub 2020 Jul 15.
5
Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.白细胞介素-1受体阻断与具有巨噬细胞活化综合征特征的脓毒症患者死亡率降低相关：对一项既往III期试验的重新分析
Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.
Zotero 插件